0
2017
Potential Analysis Of Human Dna Vaccines Market

Potential Analysis of Human DNA Vaccines Market

by Forecast Scenario Analysis (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2020-2030
Update Available On-Demand

Report Code: A01978
Pages: 120
Jun 2017 | 9814 Views
Author(s) : Abha T
Tables: 25
Charts: 35
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Potential Analysis Of Human Dna Vaccines Market

Request Now !

Potential Analysis Of Human Dna Vaccines Market Overview:

Global Potential Analysis of Human DNA Vaccines Market is expected to account for $3,762 million in 2020 and reach $9,337 million by 2030, by growing at a CAGR of 9.5% during the period, 2020 - 2030.

A DNA vaccine is a small, circular DNA plasmid that encodes one or more protein antigens under the control of a promoter to produce a specific immune response against disease. DNA vaccines are the third-generation vaccines specifically designed to overcome the unsought properties of conventional vaccines. Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity. DNA vaccines have potential advantages over traditional methods, for example, low risk of infection, easy transportation, and stability at room temperature. The potential of global human DNA vaccines market is expected to be rapid, owing to property of DNA vaccines of specific antigen targeting, reduced risk of infection compared to conventional vaccines, and improved stability. Moreover, relative ease of large-scale manufacturing compared to traditional approach and low storage requirement are anticipated to be present few key market opportunities.

According to the World Health Organization, ~18 million deaths occurred due to the unavailability of effective treatment for infectious disease in 2014, which demonstrates the global burden of infectious disease, providing an opportunity for DNA vaccine manufacturers. Moreover, rapid development in the field of molecular biology, immunology, and DNA synthesis is further expected to drive the growth of this market. Factors that may lead to increased demand for DNA vaccines include inefficient drug therapies and increased microbial resistance to existing antimicrobials and antibiotics treatments in the future.

Potential Analysis of Human DNA Vaccines Market Segmentation

Potential analysis of human DNA vaccines market segmentation

Segment Review

The global potential analysis of human DNA vaccines market is analyzed based on forecast scenario, such as rapid growth, moderate growth, and low growth. In the rapid growth scenario, maximum percentage of total population having infectious diseases, HIV, cancer, and other diseases is estimated to be vaccinated in the first year of DNA vaccine.

Geographical Review

Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is expected to possess the highest market share, owing to availability of advanced healthcare facilities, followed by Europe, in 2020. However, Asia-Pacific is anticipated to grow at the highest rate in future, due to increase in pool of patient population, rise in geriatric population, and growth in government investments for development of better healthcare facilities and R&D activities.

High Prevalence of Diseases

DNA vaccine involves the administration of DNA components that stimulate protective immunity against a specific infectious agent. The demand for vaccines has increased significantly over the past few years, owing to high incidence of diseases worldwide. These vaccines are highly efficient in preventing infectious diseases, and hence offer opportunity for the market players.

Introduction of DNA vaccines would facility eradication of diseases, such as cancer, hepatitis, HIV, and others. In addition, vaccines are essentially recommended for travelers as they are at a high risk of exposure to various diseases. For instance, travelers are advised to be vaccinated against cholera, hepatitis, meningococcal diseases, Japanese encephalitis, typhoid fever, yellow fever, rabies, polio, and tick-borne encephalitis while traveling. The incidence of aforementioned diseases in selective travel destinations has increased the need for DNA vaccines across different geographies. Furthermore, certain diseases require routine vaccinations, such as cholera; dengue; diphtheria, tetanus, pertussis (DTP), haemophilus influenza type B; hepatitis A; hepatitis B; and human papilloma virus. Furthermore, increase in incidence of pneumococcal diseases and influenza boosts the demand for DNA vaccines. In addition, DNA vaccines provide both humoral and cell-mediated immunity, thus having a wide application area.

The major selected clinical targets for DNA vaccines are influenza, human papillomavirus, and HIV. According to the World Health Organization, cervical cancer (caused due to HPV) is the third leading cause of death worldwide. Preventive HPV vaccines, such as Gardasil (Merck) and Cervarix (GlaxoSmithKline) have been developed, in 2006 and 2009, respectively. But the impact of these vaccines is slow due to high economic burden and high incidence of HPV. Thus, DNA vaccines can provide strong cellular response, and hence provide faster immunization against HPV. Several DNA vaccine clinical trials have been recently completed or are currently ongoing, such as ZYC101 (Eisai Pharmaceuticals) has completed phase I trial. HPV-16 and HPV-18 E6/E7 are being evaluated in a phase I clinical trial (Inovio Pharmaceuticals).

The key players profiled in the report include Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.

Key Market Benefits of the Report:

  • It offers an in-depth study of the global potential market for human DNA vaccines market based on the current disease prevalence, target population, and pricing for generating market size and forecast from 2020 to 2030
  • It provides potential analysis of opportunities to understand different aspects of the human DNA vaccines that are currently under various phases of clinical trials, along with the variants that would gain prominence in the future
  • It covers vaccine pipeline products against DNA, which are under various clinical stages
  • It profiles key market players and their strategies to understand the various technologies adopted by them to manufacture DNA vaccines

Potential Analysis of Human DNA Vaccines Market Key Segment:

By Forecast Scenario Analysis

  • Rapid Growth Scenario
  • Moderate Growth Scenario
  • Low Growth Scenario

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
 

Loading Table Of Content...


 
 

A DNA vaccine consists of genetically engineered DNA of the antigen and is administered in the body, which leads to antibody production. DNA vaccines are safer and more stable than traditional vaccines. Selected clinical targets for DNA vaccines are influenza, HPV, and HIV. Since the discovery of DNA vaccines, i.e., 20 years ago, intensive R&D activities have been done to understand the basic biology and working of DNA vaccines. Numerous vaccines are under different phases of clinical trials such as VGX-3100 in Phase II trial, INO-3112 in phase I trial, and others.

DNA vaccines are advantageous as they are economical to produce as compared to recombinant protein vaccines, and easier to transport, use, and store. DNA vaccines are highly specific for diseases and have a faster mode of action than traditional vaccines.

North America is expected to dominate the DNA vaccines market, owing to high incidence of infectious diseases such as cancer, HIV, and others.

Major companies involved operating in this market are Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS

Purchase Full Report of
Potential Analysis Of Human Dna Vaccines Market

Start reading instantly.
This Report and over 19,300+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,217
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jun 2018 - Jun 2019)
  • Data Pack
  • $3,574
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2018 - Jun 2019)
  • Single User
  • $4,999
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2018 - Jun 2019)
  • Five Users
  • $6,004
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2018 - Jun 2019)
  • Enterprise
    License/PDF

  • $9,373
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2018 - Jun 2019)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers